United Therapeutics (UTHR) Misses Q4 EPS by 8c
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $487.61 -0.54%
EPS Growth %: -10.1%
Financial Fact:
Total revenues: 408.2M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -10.1%
Financial Fact:
Total revenues: 408.2M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $4.36, $0.08 worse than the analyst estimate of $4.44. Revenue for the quarter came in at $614.7 million versus the consensus estimate of $575.1 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
- JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
